# **OPEN** Research Article

# A Work in Progress: National Opioid Prescription Reductions Across Orthopaedic Subspecialties in a Contemporary Medicare Sample of 5,026,911 Claims

Alexander J. Acuña, BS Tarun K. Jella, MPH Linsen T. Samuel, MD, MBA Thomas B. Cwalina, MBA Todd S. Kim, MD Atul F. Kamath, MD

From the Department of Orthopaedic Surgery, Cleveland Clinic Foundation, Cleveland, OH (Acuña, Jella, Dr. Samuel, Cwalina, Dr. Kamath), and the Department of Orthopaedic Surgery, Sutter Health–Burlingame Center, Burlingame, CA (Dr. Kim).

Correspondence to Dr. Kamath: kamatha@ccf.org

Dr. Kamath or an immediate family member has received IP rovalties from Innomed: is a member of a speakers' bureau or has made paid presentations on behalf of DePuy Synthes and Zimmer Biomet; serves as a paid consultant to DePuy Synthes and Zimmer Biomet; has stock or stock options held in Zimmer Biomet, Johnson & Johnson, and Procter & Gamble; has received research or institutional support from Signature Orthopaedics; and serves as a board member, owner, officer, or committee member of AAOS, AAHKS, and Anterior Hip Foundation. Dr. Kim or an immediate family member serves as a paid consultant to Integra and serves as a board member, owner, officer, or committee member of AAOS, Abbott Society, UCSF, and Health Volunteers Overseas/Orthopaedics Overseas. None of the following authors or any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Acuña, Jella, Dr. Cwalina, and Dr. Kamath.

JAAOS Glob Res Rev 2021;5:1-12

DOI: 10.5435/JAAOSGlobal-D-21-00080

Copyright 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### ABSTRACT

**Introduction:** As the opioid epidemic continues in the United States, efforts by orthopaedic surgeons to reduce opioid prescriptions remain critical. Although previous studies have demonstrated reductions in prescriptions across surgical specialties, there is limited information regarding contemporary trends in opioid prescriptions across orthopaedic subspecialties. Our analysis sought to estimate the frequency and trends of opioid prescriptions among Medicare Part D enrollees.

Methods: The Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use Files from Centers of Medicare and Medicare from 2014 to 2018 were analyzed. These data were merged with the National Provider Identifier Registry to identify the subspecialty of providers. Prescriber opioid prescription rate, days per claim, and claims per patient were calculated. Temporal trends were tested using linear regression. Poisson regression was used to calculate annual adjusted incidence rate ratios while controlling for year, surgeon sex, average patient comorbidity risk score, and average patient age. Results: We analyzed 5,026,911 opioid claims prescribed to 2,661,762 beneficiaries. Among all orthopaedic surgeons, the opioid prescription rate per 100 beneficiaries significantly decreased over the study period from 52.99 (95% CI, 52.6 to 53.37) to 44.50 (44.06 to 44.93) (P = 0.002). This decrease was observed for each subspecialty (all P values < 0.05). Similar significant reductions were appreciated across cohorts in the number of claims per beneficiary (all P values < 0.05). The opioid prescription rate among all orthopaedic surgeons and each subspecialty decreased significantly over the study period after controlling for various patient and surgeon characteristics (all *P* values < 0.05).

**Conclusion:** Orthopaedic surgeons across subspecialties have reduced their rates of opioid prescriptions over recent years. Although

increased prescription-limiting legislation, alternative methods of pain control, and prescriber reeducation regarding the correct quantity of opioids needed for postoperative pain relief, ongoing research, and efforts are needed to translate these reductions into clinically meaningful changes.

s the number of deaths attributed to the opioid epidemic continues to rise in the United States,<sup>1</sup> there remain ongoing efforts among healthcare systems and governing agencies to limit the overprescription of opioid analgesics by healthcare providers.<sup>2</sup> Given that orthopaedic surgeons have historically been identified as some of the highest prescribers of opioid medications,<sup>3</sup> the appropriate use of these medications for musculoskeletal pain relief has been extensively evaluated.<sup>2</sup> Despite these efforts and studies across orthopaedic subspecialties demonstrating adverse outcomes associated with perioperative opioid use, large quantities of opioids continue to be frequently prescribed for patients undergoing orthopaedic procedures.<sup>4,5</sup>

Although legislation targeting overprescription, prescription drug monitoring programs, and alternative pain alleviation strategies have emerged over recent years, it is unclear how this has affected the amount of opioid medication prescribed by orthopaedic surgeons. Analyses evaluating changes in opioid prescribing patterns over time have primarily been limited to other medical and surgical subspecialties,<sup>6,7</sup> with significant limitations demonstrated among studies exploring these temporal trends in orthopaedic surgery. Notably, although Romman et al8 demonstrated a 16% reduction in opioid claims among providers classified under orthopaedic surgery between 2013 and 2017, these authors failed to include orthopaedic hand surgeons, did not stratify by subspecialty, and did not report any statistics in their analysis. Therefore, given the limitations in the current literature, more comprehensive analyses of how opioid prescription habits among orthopaedic surgeons have changed over contemporary time frames are needed.

As part of the mitigation efforts to control the opioid epidemic, there have been continual efforts to reduce opioid prescriptions given by orthopaedic surgeons. Although previous studies have demonstrated reductions in prescriptions across surgical specialties, there is a paucity of information regarding contemporary trends in opioid prescriptions across orthopaedic subspecialties. This information could help the American Academy of Orthopaedic Surgeons (AAOS), as well as related policymakers and leadership societies, recognize the efficacy of previous efforts to subsequently improve future reduction strategies. Therefore, our analysis sought to evaluate the frequency and trends of opioid prescriptions provided by orthopaedic surgeons to Medicare Part D enrollees between 2014 and 2018. In addition, we aimed to evaluate these trends by the subspecialty of the prescribing orthopaedic surgeon.

#### **Methods**

#### Databases

The Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File (PUF) provides information on prescription drugs prescribed by physicians and healthcare providers paid through the Medicare Part D Prescription Drug Program. This data set contains individual provider-level information, such as sex, practice location, and total prescription claim count. In addition, data regarding the Medicare patient population of each provider are available, including average patient age and mean Centers for Medicare and Medicaid hierarchical condition category comorbidity risk score. The data set additionally includes opioid-specific prescription data, such as opioid claim counts, opioid day supply, and the number of patients receiving opioids from each provider registered for Medicare Part D. According to the PUF methodology files, each included claim represents either an original opioid prescription or a refill.9

These data were merged with the publicly available National Plan and Provider Enumeration System of the Centers for Medicare and Medicaid. This registry organizes all healthcare providers who are currently practicing by their National Provider Identifier (NPI), a unique identification number assigned to any Health Insurance Portability and Accountability Act covered entity. This includes healthcare organizations and individual providers. Information available from the NPI registry includes the sex and practice location of providers, as well as their discrete subspecialty taxonomy codes.<sup>10</sup> All included information is selfreported by providers when applying for this NPI number.

#### **Data Selection**


The Part D Prescriber PUFs from 2014 to 2018 were queried for all providers whose specialty was listed as one

Table '	1.	Cohort	Demographics	by	Year	of Study	and	Orthopaedic	Subspecialty
---------	----	--------	--------------	----	------	----------	-----	-------------	--------------

Year	2014	2015	2016	2017	2018
Overall, total claim count	2,235,553	2,214,655	2,268,251	2,291,115	2,250,051
Overall, opioid claim count (% of total)	1,097,065 (49.07)	1,042,574 (47.08)	1,034,121 (45.59)	953,980 (41.64)	899,171 (39.96)
Total no. of Medicare Part D patients	845,367	886,329	917,574	932,261	938,183
Total no. of Medicare Part D patients receiving opioid prescriptions (% of total)	523,163 (61.89)	543,156 (61.28)	548,555 (59.78)	536,651 (57.56)	510,237 (54.39)
Total no. of orthopaedic surgeons	N = 7,407	N = 7,480	N = 7,478	N = 7,416	N = 7,306
Subspecialty, no. (% of total)					
Adult Reconstruction	1,023 (13.8)	1,040 (13.9)	1,046 (14.0)	1,048 (14.1)	1,035 (14.2)
Foot and Ankle	572 (7.7)	570 (7.6)	582 (7.8)	573 (7.7)	590 (8.1)
Hand Surgery	1,823 (24.6)	1,842 (24.6)	1,848 (24.7)	1,855 (25.0)	1,820 (24.9)
Ortho Trauma	476 (6.4)	496 (6.6)	493 (6.6)	508 (6.9)	486 (6.7)
Spine Surgery	1,484 (20.0)	1,491 (19.9)	1,472 (19.7)	1,450 (19.6)	1,430 (19.6)
Sports Medicine	2,029 (27.4)	2,041 (27.2)	2,037 (27.2)	1,982 (26.7)	1,945 (26.6)
Female, no. (% within specialty)					
Adult Reconstruction	25 (2.4)	27 (2.6)	27 (2.6)	23 (2.2)	25 (2.4)
Foot and Ankle	62 (10.8)	62 (10.9)	62 (10.7)	66 (11.5)	69 (11.7)
Hand Surgery	206 (11.3)	213 (11.6)	216 (11.7)	217 (11.7)	220 (12.1)
Ortho Trauma	30 (6.3)	34 (6.9)	33 (6.7)	34 (6.7)	36 (7.4)
Spine Surgery	21 (1.4)	22 (1.5)	23 (1.6)	20 (1.4)	20 (1.4)
Sports Medicine	74 (3.6)	75 (3.7)	75 (3.7)	66 (3.3)	72 (3.7)
Medicare patient age, mean (SD)					
Adult Reconstruction	70.15 (2.84)	70.30 (2.79)	70.67 (2.58)	70.97 (2.52)	71.24 (2.36)
Foot and Ankle	67.72 (3.07)	67.81 (3.10)	68.17 (2.85)	68.55 (2.91)	69.00 (2.63)
Hand Surgery	69.16 (3.07)	69.35 (2.96)	69.63 (2.73)	69.91 (2.60)	70.18 (2.47)
Ortho Trauma	66.95 (4.09)	67.25 (4.09)	67.81 (4.06)	68.38 (3.55)	68.80 (3.47)
Spine Surgery	68.94 (3.38)	69.18 (3.30)	69.49 (3.10)	69.80 (2.96)	70.25 (2.86)
Sports Medicine	69.05 (3.14)	69.29 (2.96)	69.44 (2.93)	69.70 (2.82)	69.96 (2.62)
Medicare patient risk score, mean (SD)					
Adult Reconstruction	1.07 (0.24)	1.11 (0.23)	1.12 (0.24)	1.11 (0.24)	1.12 (0.23)
Foot and Ankle	1.17 (0.27)	1.23 (0.29)	1.21 (0.30)	1.21 (0.28)	1.20 (0.29)
Hand Surgery	1.07 (0.21)	1.16 (0.25)	1.15 (0.24)	1.16 (0.24)	1.16 (0.26)
Ortho Trauma	1.36 (0.35)	1.41 (0.36)	1.44 (0.39)	1.46 (0.37)	1.46 (0.40)
Spine Surgery	1.11 (0.21)	1.17 (0.21)	1.18 (0.21)	1.18 (0.22)	1.19 (0.22)
Sports Medicine	1.00 (0.22)	1.06 (0.23)	1.06 (0.23)	1.06 (0.23)	1.05 (0.23)

of the following: Orthopaedic Surgery, Orthopedic Surgery, or Hand Surgery. The subsequent list of surgeons was verified using taxonomy code 207X00000X— Orthopaedic Surgery (eg, plastic surgeons who practice hand surgery were excluded). We then further stratified surgeons based on taxonomy codes pertaining to orthopaedic subspecialties. Specifically, the following codes were identified: 207XS0114X—Adult Reconstruction, 207XX0004X—Foot and Ankle, 207XS0106X—Hand Surgery, 207XX0801Z—

### Figure 1




Line graph showing opioid prescriptions per 100 Medicare beneficiaries (2014 to 2018).

Orthopaedic Trauma, 207XS0117X—Spine Surgery, and 207XX0005X—Sports Medicine. The taxonomy codes for surgeons without these specific taxonomy codes were then manually reviewed by two authors (A.J.A. and T.K.J.) and assigned to an orthopaedic

subspecialty if certain taxonomy classifications were deemed appropriate. For example, surgeons with the taxonomy code 2086S0105X (Surgery of the Hand) were allocated to the Hand Surgery cohort, whereas those with taxonomy code 2086S0127X (Trauma

#### Figure 2



Histogram demonstrating the distribution of opioid prescription rates among included orthopaedic surgeons.

Table	2. Trends in Opioic	Table 2. Trends in Opioid Prescription Rate per 100 Medicare Beneficiaries by Orthopaedic Subspecialty	100 Medicare Benet	ficiaries by Orthopa	edic Subspecialty		
Year	Overall	Adult Reconstruction	Foot and Ankle	Hand Surgery	<b>Orthopaedic Trauma</b>	Spine Surgery	Sports Medicine
2014	52.99 (52.60-53.37)	47.35 (46.37-48.32)	48.32 (47.07-49.57)	48.32 (47.07-49.57) 60.68 (59.88-61.48)	59.86 (58.34-61.39)	50.03 (49.27-50.8)	50.83 (50.12-51.54)
2015	51.22 (50.83-51.62)	45.09 (44.07-46.11)	47.39 (46.09-48.7)	47.39 (46.09-48.7) 59.78 (58.99-60.58)	57.76 (56.2-59.32)	47.49 (46.71-48.27)	48.83 (48.11-49.55)
2016	49.84 (49.43-50.25)	43.31 (42.27-44.36)	45.69 (44.44-46.95)	45.69 (44.44-46.95) 59.13 (58.31-59.94)	56.33 (54.75-57.92)	46.32 (45.52-47.12)	46.92 (46.2-47.65)
2017	47.54 (47.12-47.96)	40.17 (39.13-41.21)	43.88 (42.58-45.19)	57.37 (56.54-58.2)	55.33 (53.73-56.92)	42.88 (42.06-43.69)	44.71 (43.97-45.45)
2018	44.50 (44.06-44.93)	36.62 (35.54-37.70)	40.70 (39.36-42.03)	40.70 (39.36-42.03) 55.09 (54.20-55.97)	52.29 (50.68-53.90)	39.86 (39.01-40.71)	41.39 (40.63-42.15)
P value	0.002	0.001	0.004	0.006	0.002	0.001	<0.001

All values expressed as the percent (%) of total Part D claims represented by opioid claims (95% CI).

**Research** Article

Surgery) were assigned to the Orthopaedic Trauma cohort. Surgeons with taxonomy codes pertaining to other medical specialties and other healthcare professions (including registered nurses, physician assistants, chiropractors, and podiatrists) were excluded. We similarly excluded any surgeons with the taxonomy code 390200000X-Student in an Organized Health Care Education/Training Program.

#### Statistical Analysis

Univariate statistics were used to describe orthopaedic surgeon cohorts both across years and across specialties. For the primary analysis, prescriber opioid prescription rate, days per claim, and claims per patient were calculated. We calculated an opioid prescription rate (opioid claim count/total claim count), days per claim (opioid day supply/opioid claim count), and claims per patient (opioid claim count/opioid patient count). All annual prescriber averages for each of the three values were calculated over the period. A histogram was created to evaluate how the distribution of opioid prescription rates among orthopaedic surgeons changed from 2014 to 2018. In addition, all data were stratified to calculate yearly averages for all individual orthopedic subspecialties. Temporal trends were tested using linear regression.


Furthermore, the opioid prescription rate was modeled using a Poisson regression.<sup>11</sup> The model used year, surgeon sex, average patient comorbidity risk score, and average patient age to predict annual adjusted incidence rates of opioid prescriptions. Poisson models were fitted to both the overall orthopaedic cohort and the individual subspecialty cohorts. Estimates of annual adjusted incidence rate ratios for the models were used to investigate changes in opioid prescription rate over time while controlling for included variables. All statistics were conducted using R version 4.0.2 (R Foundation for Statistical Computation, Vienna, Austria). A P-value less than 0.05 was considered statistically significant.

## **Results**

#### Study Cohort

In total, we analyzed 5,026,911 opioid claims prescribed to 2,661,762 Medicare Part D beneficiaries between January 1, 2014, and December 31, 2018 (Table 1). This included claims submitted by an average of 7,417 unique orthopaedic surgeons per year. The most recent study cohort (as of December 31, 2018) comprised

#### Figure 3



Line graph showing the average number of opioid claims per patient (2014 to 2018).

7,306 surgeons, with the most common specialties being Sports Medicine (1,945; 26.6%), Hand Surgery (1,820; 24.9%), Spine Surgery (1,430; 19.6%), and Adult Reconstruction (1,035; 14.2%). Female orthopaedic surgeons comprised 6.0% of the study cohort, whereas the proportion of female surgeons across subspecialties ranged from 12.1% of hand surgeons to 1.4% of spine surgeons. The average mean patient age (SD) for subspecialty surgeons ranged from 68.38 (3.47) among orthopaedic trauma surgeons to 71.24 (2.36) among adult reconstruction surgeons. In addition, the hierarchical condition category risk score (SD) ranged from 1.05 (0.23) among sports medicine surgeons to 1.46 (0.40) among orthopaedic trauma surgeons (Table 1).

#### **Prescription Rate**

Among all orthopaedic surgeons, the rate of opioid prescription claims per 100 Medicare beneficiaries significantly decreased from 52.99 (95% CI, 52.60 to 53.37) in 2014 to 44.50 (44.50 to 44.93) in 2018 (P = 0.002) (Figure 1). When evaluating prescription rate distribution, rates in 2014 appeared normally distributed, with 57.18% of providers prescribing over 50 claims per 100 beneficiaries. Conversely, the distribution of prescription rates in 2018 was rightly skewed, with only 37.49% of orthopaedic surgeons prescribing over a rate of 50.00 (Figure 2). Statistically significant decreases in opioid prescription rates were similarly observed for each orthopaedic subspecialty (Figure 1; Table 2). The largest decreases were observed among adult reconstruction surgeons (47.35 [46.37 to 48.32] in 2014 to 36.62 [35.54 to 37.70] in 2018; P = 0.001) and spine surgeons (50.03 [49.27 to 50.8] in 2014 to 39.86 [39.01 to 40.71] in 2018; P = 0.001). The smallest decrease in opioid prescription rates was observed among hand surgeons (60.68 [59.88 to 61.48] in 2014 to 55.09 [54.20 to 55.97] in 2018; P value = 0.006) (Table 2).

#### **Opioids Claims Per Patient**

For all orthopaedic surgeons, the average number of opioid claims per patient also decreased significantly from 1.906 (1.888, 1.923) in 2014 to 1.623 (1.607, 1.638) in 2018 (P = 0.017) (Figure 3). Similar significant decreases were demonstrated when segregating for each subspecialty (all P values < 0.05) (Figure 3; Table 3). The largest decrease was seen for spine surgeons from 2.362 (2.337 to 2.387) claims per beneficiary in 2014 to 1.974 (1.953 to 1.996) (P = 0.029).

#### Days Per Opioid Claim

When evaluating all orthopaedic surgeons, the number of days per opioid claim remained relatively stable between 2014 (9.906 [9.793 to 10.019]) and 2018 (8.835 [8.727 to 8.943]) (P = 0.219) (Figure 4). A similar nonsignificant

Table	<b>3.</b> Trends in Opioic	Table 3. Trends in Opioid Claims per Patient by Orthopaedic Subspecialty	Orthopaedic Subsp	ecialty			
Year	Overall	Adult Reconstruction	Foot and Ankle	Hand Surgery	<b>Orthopaedic Trauma</b>	Spine Surgery	Sports Medicine
2014	1.906 (1.888-1.924)	1.998 (1.984-2.013)	1.832 (1.817-1.848)	1.832 (1.817-1.848) 1.483 (1.473-1.493)	1.906 (1.892-1.921)	2.362 (2.337-2.387)	1.926 (1.911-1.941)
2015	1.746 (1.731-1.761)	1.824 (1.812-1.836)	1.689 (1.675-1.702)	1.689 (1.675-1.702) 1.397 (1.39-1.405)	1.707 (1.695-1.718)	2.117 (2.095-2.139)	1.776 (1.763-1.789)
2016	1.715 (1.699-1.731)	1.785 (1.773-1.796)	1.641 (1.628-1.654)	1.641 (1.628-1.654) 1.37 (1.362-1.377)	1.68 (1.669-1.692)	2.087 (2.064-2.109)	1.753 (1.739-1.768)
2017	1.671 (1.655-1.686)	1.753 (1.742-1.765)	1.605 (1.592-1.619)	1.605 (1.592-1.619) 1.332 (1.325-1.34)	1.646 (1.635-1.658)	2.028 (2.006-2.05)	1.707 (1.693-1.722)
2018	1.623 (1.607-1.638)	1.727 (1.715-1.738)	1.528 (1.515-1.541)	1.528 (1.515-1.541) 1.298 (1.291-1.306)	1.606 (1.595-1.618)	1.974 (1.953-1.996)	1.647 (1.631-1.663)
P value	0.017	0.036	0.007	0.005	0.039	0.029	0.013

All values expressed as number of opioid claims divided by the total number of Medicare Part D beneficiaries (95% CI).

Alexander J. Acuña, BS, et al

trend was observed for included orthopaedic subspecialties, with the exception of hand surgery (Figure 4; Table 4). Specifically, hand surgeons reduced the number of days per claim from 6.704 (6.637 to 6.771) in 2014 to 5.463 (5.402 to 5.524) in 2018 (P = 0.042).

#### **Poisson Regression**


When adjusting for potentially confounding factors, the opioid prescription rate among all orthopaedic surgeons decreased significantly between 2014 and 2018 (annual adjusted incidence rate ratio = 0.833; 95% CI, 0.830 to 0.835; P < 0.05). Significant decreases in prescription rate were additionally demonstrated when evaluating each subspecialty independently (all *P* values < 0.05) (Table 5). As observed in the unadjusted analysis, adult reconstruction surgeons (0.784 [0.779 to 0.790]; P < 0.05) and spine surgeons (0.804 [0.800 to 0.809]; P < 0.05) as whe greatest decrease in opioid prescription rates over the study period, whereas hand surgeons saw the most modest decrease (0.946 [0.94 to 0.953]; P < 0.05) (Table 5).

#### Discussion

In response to the ongoing opioid epidemic, the orthopaedic community-one of the larger providers of narcotic prescriptions-has sought methods of curbing overprescription while safely and effectively managing patients' perioperative pain. Although various changes in legislation, institutional guidelines, and pain management techniques have emerged in recent years, there is limited information regarding how this has influenced the prescribing practices of orthopaedic surgeons across the nation. Therefore, our analysis aimed to provide a comprehensive, nationwide analysis of opioid prescription habits among orthopaedic surgeons caring for Medicare Part D patients. Although there were no substantial changes in the days per opioid claim over this study period, our analysis demonstrated statistically significant decreases in opioid prescription rates and the number of claims per beneficiary for all analyzed subspecialties. These findings were similarly demonstrated while controlling for various prescriber and patient characteristics.

Although the present analysis demonstrated statistically significant reductions in opioid prescriptions, it remains unclear whether these decreases can be considered clinically significant. According to a recent report by the Opioid Task Force of the American Medical Association, there was a 37.1% decrease in opioid prescriptions from

#### Figure 4



Line graph showing the average days of prescription per opioid claim (2014 to 2018).

244.5 million in 2014 to 153.7 million in 2019.<sup>12</sup> Our analysis demonstrated a more modest reduction of approximately 18%. However, this still translated to a reduction of 8.49 claims per 100 beneficiaries and a decrease in total opioid claims of 197,894. Therefore, although our analysis suggests that orthopaedic surgeons have meaningfully reduced opioid prescriptions over recent years to reduce the harmful effects of these medications, our findings additionally serve to encourage further reduction by both the AAOS and the wider orthopaedic community to ensure clinically notable change.

Multiple analyses have reported similar contemporary decreases in opioid prescriptions across orthopaedic subspecialties.<sup>11,13,14</sup> Flanagan et al<sup>13</sup> recently evaluated changes in opioid prescribing between 2012 and 2017 for orthopaedic trauma patients. After matching patients from each year by multiple variables, such as comorbidity burden and fracture location, the authors found significantly decreased total prescribed morphine milligram equivalents (MMEs) (1,110 versus 1,680 mg; P = 0.001) and refill amounts (766 versus 1,140 mg; P = 0.037) among the 2017 cohort compared with patients in 2012.13 Using a large claims database, Harris et al demonstrated a significant reduction in the number of patients receiving  $\geq 90$  MMEs after anterior cervical disectomy and fusion between 2010 and 2015 (1,811 [48%] versus 1,278 [43%]; P < 0.001).<sup>11</sup> Goldman

et al<sup>14</sup> similarly reported a 27% decrease in oral MMEs when comparing patients undergoing primary total hip arthroplasty between 2014 and 2018. Our analysis further supports these findings by demonstrating statistically significant reductions in opioid prescriptions across a larger, national sample of orthopaedic surgeons.

Although there are various factors that likely have contributed to the decrease in opioid claims and prescription rates demonstrated in our analysis, federal and state legislation aimed at reducing the overprescription of opioids is considered one of the most influential.<sup>15,16</sup> This has been reflected across the orthopaedic literature, with multiple studies demonstrating significant reductions in opioid prescriptions after the implementation of these laws.<sup>17,18</sup> Glogovac et al reported significant reductions in both the overall number of opioid pills (49.7 versus 36.2; P < 0.001) and average MME per prescription (382.1 versus 275.2 mg; P = 0.016) when comparing patients undergoing surgical management of ankle fractures before and after Ohio implemented an Opioid Prescriber Law.<sup>17</sup> After the passage of the Strengthen Opioid Misuse Prevention Act of 2017 (STOP Act) in North Carolina, Aran et al<sup>18</sup> found a 35% decrease (27,374 mg; 95% CI, 13,226 to 41,523 mg; P = 0.0003) in total MMEs prescribed by orthopaedic surgeons at their institution. Coupled with the findings of the present analysis, these results should further encourage lawmakers to advocate for the

Overall     Adult Reconstruction       9.906 (9.793-10.019)     10.976 (10.882-11.071)	Foot and Ankle 8.791 (8.717-8.864)	Hand Surgery			
19) 10.976 (10.882-11.071)	8.791 (8.717-8.864)		Orthopaedic Trauma	Spine Surgery	Sports Medicine
		8.791 (8.717-8.864) 6.704 (6.637-6.771)	10.9 (10.801-11.000)	14.402 (14.268-14.536)	9.036 (8.952-9.12)
10.402 (10.283-10.520) 11.767 (11.667-11.868)	9.247 (9.171-9.323)	9.247 (9.171-9.323) 6.785 (6.715-6.856)	11.878 (11.773-11.983)	15.2 (15.066-15.334)	9.429 (9.342-9.516)
10.264 (10.146-10.381) 11.782 (11.679-11.883)	9.042 (8.965-9.120)	9.042 (8.965-9.120) 6.601 (6.532-6.671)	11.812 (11.708-11.915)	15.038 (14.905-15.171)	9.331 (9.246-9.417)
9.946 (9.830-10.063) 11.330 (11.233-11.428)	8.877 (8.8-8.954)	8.877 (8.8-8.954) 6.188 (6.121-6.255)	11.505 (11.403-11.608)	14.791 (14.659-14.923)	9.097 (9.014-9.18)
8.835 (8.727-8.943) 9.916 (9.830-10.001)	7.749 (7.679-7.819)	5.463 (5.402-5.524)	9.991 (9.901-10.081)	13.182 (13.049-13.314) 8.269 (8.191-8.347)	8.269 (8.191-8.347)
0.363	0.219	0.042	0.458	0.328	0.238
191		9.916 (9.830-10.001) 0.363	9.916 (9.830-10.001) 7.749 (7.679-7.819) 5.463 (   0.363 0.219	9.916 (9.830-10.001)     7.749 (7.679-7.819)     5.463 (5.402-5.524)       0.363     0.219     0.042	9.916 (9.830-10.001)     7.749 (7.679-7.819)     5.463 (5.402-5.524)     9.991 (9.901-10.081)       0.363     0.219     0.042     0.458

All values expressed as the total day supply assigned to opioid claims divided by total opioid claims (95% Cl).

Alexander J. Acuña, BS, et al

widespread passage and implementation of similar prescription-limiting legislation. For states in which these have yet to be enacted, individual healthcare institutions should consider implementing similar protocols to further help combat the current opioid crisis.<sup>19,20</sup>

Our findings may also reflect an increased shift toward alternative methods of pain management for orthopaedic patients. Specifically, the implementation of multimodal and multidisciplinary pain management protocols has become increasingly popular, given their demonstrated effectiveness at reducing opioid consumption across orthopaedic subspecialties.<sup>21-23</sup> Notably, Moutzouros et al<sup>21</sup> found that 45% of patients undergoing sports procedures did not require breakthrough opioid analgesics when a multimodal protocol was used. Similarly, a recent analysis by Elkassabany et al<sup>22</sup> found significantly higher quality of recovery scores at all time frames (*P*-values < 0.05) despite lower total MME consumption (111.2 versus 76.8 mg; P <0.05) among shoulder arthroscopy patients in their multimodal pain management cohort compared with matched controls. Although continued research is needed to evaluate the efficacy of these protocols following more invasive orthopaedic procedures, providers should continue to consider methods of pain control that do not include opioid medications.

The authors acknowledge that despite the positive findings reported in our analysis, significant work remains in the orthopaedic community's push against opioid overprescription and abuse.<sup>3</sup> A cornerstone of this effort relates to continued surgeon education regarding safe prescription practices and how to educate patients regarding the harms of opioid medications and misuse.<sup>24-27</sup> These education programs have resulted in significant reductions in both the amount of opioids prescribed among orthopaedic surgeons and the opioids used by patients.<sup>24,28-30</sup> Notably, Stepan et al<sup>30</sup> reported significant decreases in the number of pills and total MMEs prescribed for sports (all *P*-values < 0.001) and hand (all *P*-values < 0.001) procedures after the implementation of an opioid prescribing education program at their institution. Similarly, there continues to be a push for uniform prescription guidelines, given inconsistent prescribing practices reported among providers.<sup>31-34</sup> Although the development of consistent guidelines is challenged by wide variations in opioid consumption reported in the current literature,<sup>35,36</sup> the implementation of institution-specific prescription protocols has resulted in notable decrease in excessive practices.37,38 prescription Therefore, continued research and development of these standardized

Table 5. Poisso	on Regression Res	Table 5. Poisson Regression Results for Adjusted Opioid Prescription Rate Ratios by Orthopaedic Subspecialty	id Prescription Rat	te Ratios by Ortho	paedic Subspecialty		
aIRR (95% CI)	Overall	Adult Reconstruction	Foot and Ankle	Hand Surgery	<b>Orthopaedic Trauma</b>	Spine Surgery	Sports Medicine
Female	0.998 (0.993-1.003)	0.806 (0.791-0.821)	0.922 (0.909-0.936)	0.922 (0.909-0.936) 0.969 (0.962-0.976)	1.073 (1.050-1.096)	0.917 (0.905-0.930)	0.915 (0.905-0.926)
Patient risk score	1.057 (1.053-1.062)	0.996 (0.985-1.006)	1.019 (1.004-1.034)	1.019 (1.004-1.034) 0.795 (0.786-0.803)	1.175 (1.159-1.191)	1.171 (1.161-1.182)	1.069 (1.060-1.078)
Average patient age	Average patient age 0.976 (0.976-0.977)	0.967 (0.966-0.968)	0.966 (0.965-0.968)	0.966 (0.965-0.968) 0.974 (0.973-0.974)	0.984 (0.983-0.985)	0.986 (0.985-0.986)	0.974 (0.973-0.974)
Year							
2014	Reference	I	I	1	I	I	1
2015	0.960 (0.958-0.963)	0.947 (0.941-0.953)	0.980 (0.969-0.992)	0.980 (0.969-0.992) 1.012 (1.006-1.019)	0.95 (0.939-0.962)	0.943 (0.938-0.948)	0.961 (0.956-0.966)
2016	0.936 (0.933-0.938)	0.918 (0.912-0.923)	0.961 (0.949-0.972)	0.961 (0.949-0.972) 1.007 (1.001-1.014)	0.928 (0.917-0.940)	0.915 (0.910-0.920)	0.928 (0.923-0.933)
2017	0.888 (0.886-0.890)	0.859 (0.854-0.865)	0.935 (0.924-0.946)	0.979 (0.973-0.985)	0.89 (0.879-0.901)	0.855 (0.850-0.859)	0.883 (0.878-0.888)
2018	0.833 (0.83-0.835)	0.784 (0.779-0.79)	0.870 (0.859-0.880) 0.946 (0.94-0.953)	0.946 (0.94-0.953)	0.859 (0.848-0.870)	0.804 (0.800-0.809)	0.819 (0.814-0.824)

alRR = adjusted incidence rate ratios

protocols should be at the forefront of future efforts aimed at curbing the opioid epidemic.

The findings of our analysis must be considered in light of its limitations. We were unable to convert opioid claims into MMEs given limitations in the variables provided by the Medicare Part D PUF. Specifically, we were unable to control the type of opioid medication prescribed or the number of tablets given in each prescription. However, the conclusion that our analysis has drawn is more binary in nature because it is looking at reductions in the active number of opioid prescriptions rather than the specific amount prescribed per patient. Previous high-impact studies have used similar methodology when evaluating changes in opioid prescription rates without converting to MMEs.12,15,39 As many newly developed pain management regimens are aimed at eliminating opioid prescriptions entirely,<sup>21,40</sup> rather than reducing the dose per prescription, evaluating how the number of opioid prescriptions among orthopaedic surgeons has decreased still provides important information to providers and policymakers working on reducing our effect on the opioid epidemic. In addition, we are unable to evaluate the accuracy of the taxonomy codes assigned to orthopaedic surgeons in the NPI registry. However, these codes are self-reported by healthcare providers when applying for their unique NPI and, therefore, likely can be considered accurate. We were unable to evaluate how prescription rates have changed after the implementation of various legislation in each state. Specifically, for the states that have implemented related legislation, there was large variability in the years that these laws were released as well as in the specific goals these laws aimed to achieve. Only approximately 70% of Medicare beneficiaries have Medicare Part D coverage, and therefore, our findings do not represent all prescriptions written for this patient population. Similarly, we were unable to evaluate the prescription patterns of orthopaedic surgeons managing vounger populations and/or those with alternative insurance coverage. However, given that we reported on an average of 7,417 surgeons a year and over 5.03 million opioid prescriptions, our findings likely remain generalizable. Furthermore, we were unable to evaluate causes behind prescription variation between subspecialties because we did not have information regarding case-volume for each prescriber, their decision-making process for pain control, or how efforts made by related professional societies have influenced these decisions. Similarly, we were unable to control for how the age of our patients affected prescription decisions. Notably, although opioids are recommended with caution in older populations based on the Beers Criteria, other forms of pain relief, such as nonsteroidal antiinflammatory drugs may be contraindicated as well. We additionally were unable to assess changes in prescriptions for more conservative pain control medications or concomitantly prescribed medications over our study period. Similarly, over-the-counter medications, such as nonsteroidal antiinflammatory drugs, were not captured in the Medicare Part D files. Despite these limitations, we still found statistically significant reductions in opioid prescription rates across all subspecialties between 2014 and 2018.

#### Conclusion

Orthopaedic surgeons across subspecialties have markedly reduced their rates of opioid prescriptions over recent years. Although increased prescription-limiting legislation, alternative methods of pain control and prescriber reeducation regarding the correct quantity of opioids needed for postoperative pain relief have likely contributed to these reductions, ongoing research and efforts are needed to translate these reductions into clinically meaningful changes. While these findings are promising, notable work remains in the orthopaedic community's push against opioid overprescription and abuse. To continue this trend, the AAOS and the leadership of subspecialty societies should evaluate effective methods of educating patients and providers regarding the harmful effects of opioid analgesics, shared decision-making in pain control, and the optimal amount of pain medication needed following specific orthopaedic procedures.

#### References

1. Centers for Disease Control and Prevention: *Opioid Data Analysis and Resources*|*Drug Overdose*|*CDC Injury Center*. https://www.cdc.gov/ drugoverdose/data/analysis.html. Accessed October 21, 2019.

2. American Academy of Orthopaedic Surgeons (AAOS): *Opioid Use, Misuse, and Abuse in Orthopaedic Practice.* http://www.mdcalc.com/ opioid-risk-tool-ort-for-narcotic. Accessed October 21, 2019.

3. Morris BJ, Mir HR: The opioid epidemic: Impact on orthopaedic surgery. *J Am Acad Orthop Surg* 2015;23:267-271.

4. Farley KX, Wilson JM, Spencer CC, et al: Preoperative opioid use is a risk factor for revision surgery, complications, and increased resource utilization after arthroscopic rotator cuff repair. *Am J Sports Med* 2020;48:3339-3346.

5. Goplen CM, Verbeek W, Kang SH, et al: Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: A systematic review and meta-analysis. *BMC Musculoskelet Disord* 2019;20:234.

6. Schieber LZ, Guy GP, Seth P, et al: Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017. *JAMA Netw Open* 2019;2:e190665.

7. Howard R, Waljee J, Brummett C, Englesbe M, Lee J: Reduction in opioid prescribing through evidence-based prescribing guidelines. *JAMA Surg* 2018;153:285-287.

8. Romman AN, Hsu CM, Chou LN, et al: Opioid prescribing to Medicare Part D enrollees, 2013-2017: Shifting responsibility to pain management providers. *Pain Med* 2020;21:1400-1407.

9. The Centers for Medicare and Medicaid Services (CMS): *Medicare* Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File: A Methodological Overview. 2019. https:// nppes.cms.hhs.gov/. Accessed October 21, 2019.

10. Bindman AB: Using the national provider identifier for health care workforce evaluation. *Medicare Medicaid Res Rev* 2013;30.

# 11. Harris AB, Marrache M, Jami M, et al: Chronic opioid use following anterior cervical discectomy and fusion surgery for degenerative cervical pathology. *Spine J* 2020;20:78-86.

12. American Medical Association (AMA): Physicians' Progress Toward Ending the Nation's Drug Overdose and Death Epidemic Opioid Task Force 2020 Progress Report. https://www.ama-assn.org/delivering-care/ opioids/physicians-progress-toward-ending-nation-s-drug-overdoseand-death-epidemic. Accessed October 21, 2019.

13. Flanagan CD, Joseph NM, Benedick A, Vallier HA: Five-year trends in opioid prescribing following orthopaedic trauma. *J Am Acad Orthop Surg Glob Res Rev* 2020;4:e2000134.

14. Goldman AH, Griffis CE, Johnson DD, Balazs GC: Shifts in prescribers' initial postoperative opioid prescriptions following primary total hip arthroplasty between 2014 and 2018. *J Arthroplasty* 2020;35:3208-3213.

15. Hincapie-Castillo JM, Goodin A, Possinger MC, Usmani SA, Vouri SM: Changes in opioid use after Florida's restriction law for acute pain prescriptions. *JAMA Netw Open* 2020;3:e200234.

16. Dave CV, Patorno E, Franklin JM, et al: Impact of state laws restricting opioid duration on characteristics of new opioid prescriptions. *J Gen Intern Med* 2019;34:2339-2341.

17. Glogovac G, Fitts J, Henning J, Dixon TL, Laughlin RT: Patterns in opioid prescription for patients operatively treated for ankle fractures following implementation of 2017 Ohio opioid prescriber law. *Foot Ankle Orthop* 2019;4:247301141989107.

18. Aran F, Wang KY, Rosas S, Danelson KA, Emory CL: The effect of the strengthen Opioid Misuse Prevention Act on opiate prescription practices within the Orthopaedic Surgery Department of an Academic Medical Center. J Am Acad Orthop Surg Glob Res Rev 2020;4:e20.00006.

19. Lovecchio F, Premkumar A, Stepan JG, Albert TJ: Fighting back: Institutional strategies to combat the opioid epidemic: A systematic review. *HSS J* 2019;15:66-71.

20. Earp BE, Silver JA, Mora AN, Blazar PE: Implementing a postoperative opioid-prescribing protocol significantly reduces the total morphine milligram equivalents prescribed. *J Bone Joint Surg Am* 2018;100:1698-1703.

21. Moutzouros V, Jildeh TR, Khalil LS, et al: A multimodal protocol to diminish pain following common orthopedic sports procedures: Can we eliminate postoperative opioids? *Arthroscopy* 2020;36:2249-2257.

22. Elkassabany NM, Wang A, Ochroch J, Mattera M, Liu J, Kuntz A: Improved quality of recovery from ambulatory shoulder surgery after implementation of a multimodal perioperative pain management protocol. *Pain Med* 2018;20:1012-1019.

23. Maheshwari K, Avitsian R, Sessler DI, et al: Multimodal analgesic regimen for spine surgery: A randomized placebo-controlled trial. *Anesthesiology* 2020;132:992-1002.

National Opioid Prescription Reductions

24. Dwyer CL, Soong M, Hunter A, Dashe J, Tolo E, Kasparyan NG: Prospective evaluation of an opioid reduction protocol in hand surgery. *J Hand Surg Am* 2018;43:516-522.e1.

25. Syed UAM, Aleem AW, Wowkanech C, et al: Neer award 2018: The effect of preoperative education on opioid consumption in patients undergoing arthroscopic rotator cuff repair: A prospective, randomized clinical trial. *J Shoulder Elbow Surg* 2018;27:962-967.

26. Cui C, Wang LX, Li Q, Zaslansky R, Li L: Implementing a pain management nursing protocol for orthopaedic surgical patients: Results from a PAIN OUT project. *J Clin Nurs* 2018;27: 1684-1691.

27. Stanek JJ, Renslow MA, Kalliainen LK: The effect of an educational program on opioid prescription patterns in hand surgery: A quality improvement program. *J Hand Surg Am* 2015;40:341-346.

28. Warner LL, Warner PA, Eldrige JS: Orthopedic resident education on postoperative pain control: Bridging knowledge gaps to enhance patient safety. *Int J Med Educ* 2018;9:72-73.

29. Soffin EM, Waldman SA, Stack RJ, Liguori GA: An evidence-based approach to the prescription opioid epidemic in orthopedic surgery. *Anesth Analg* 2017;125:1704-1713.

30. Stepan JG, Lovecchio FC, Premkumar A, et al: Development of an institutional opioid prescriber education program and opioid-prescribing guidelines. *J Bone Joint Surg* 2019;101:5-13.

31. Ruder J, Wally MK, Oliverio M, Seymour RB, Hsu JR: Patterns of opioid prescribing for an orthopaedic trauma population. *J Orthop Trauma* 2017;31:e179-e185.

32. Welton KL, Kraeutler MJ, McCarty EC, Vidal AF, Bravman JT: Current pain prescribing habits for common shoulder operations: A survey of the American Shoulder and Elbow Surgeons Membership. J Shoulder Elbow Surg 2018;27:S76-S81.

33. Raneses E, Secrist ES, Freedman KB, Sohn DH, Fleeter TB, Aland CM: Opioid prescribing practices of orthopaedic surgeons: Results of a national survey. *J Am Acad Orthop Surg* 2019;27:e166-e172.

34. Overton HN, Hanna MN, Bruhn WE, et al: Opioid-prescribing guidelines for common surgical procedures: An expert panel consensus. *J Am Coll Surg* 2018;227:411-418.

35. Lovecchio F, Derman P, Stepan J, et al: Support for safer opioid prescribing practices: A catalog of published use after orthopaedic surgery. *J Bone Joint Surg Am* 2017;99:1945-1955.

36. Sheth U, Mehta M, Huyke F, Terry MA, Tjong VK: Opioid use after common sports medicine procedures: A systematic review. *Sports Health* 2020;12:225-233.

37. Chen EY, Betancourt L, Li L, Trucks E, Marcantonio A, Tornetta P: Standardized, patient-specific, postoperative opioid prescribing after inpatient orthopaedic surgery. *J Am Acad Orthop Surg* 2020;28: e304-e318.

38. Schommer J, Allen S, Scholz N, Reams M, Bohn D: Evaluation of quality improvement methods for altering opioid prescribing behavior in hand surgery. *J Bone Joint Surg Am* 2020;102:804-810.

39. Agarwal A, Roberts A, Dusetzina SB, Royce TJ: Changes in opioid prescribing patterns among generalists and oncologists for Medicare Part D beneficiaries from 2013 to 2017. *JAMA Oncol* 2020;6:1271-1274.

40. Hajewski CJ, Westermann RW, Holte A, Shamrock A, Bollier M, Wolf BR: Impact of a standardized multimodal analgesia protocol on opioid prescriptions after common arthroscopic procedures. *Orthop J Sports Med* 2019;7:2325967119870753.